Revolution Medicines (RVMD) Total Non-Current Liabilities (2019 - 2026)

Revolution Medicines' Total Non-Current Liabilities history runs 8 years deep, the most recent figure standing at $746.9 million for Q1 2026.

• On a quarterly basis, Total Non-Current Liabilities rose 160.76% year-over-year to $746.9 million in Q1 2026; TTM through Mar 2026 was $746.9 million, a 160.76% increase from a year earlier, with the FY2025 full-year figure at $704.7 million, up 140.97% from the prior year.
• Total Non-Current Liabilities advanced to $746.9 million in Q1 2026 per RVMD's latest filing, from $704.7 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $746.9 million in Q1 2026 and bottomed at $119.3 million in Q1 2023.
• The 5-year median for Total Non-Current Liabilities is $188.2 million (2024), against an average of $292.8 million.
• Across the five-year window, Total Non-Current Liabilities slipped 8.31% in 2023 and jumped 236.48% in 2025, its largest moves.
• Year by year, Total Non-Current Liabilities stood at $126.4 million in 2022, then soared by 85.11% to $234.1 million in 2023, then increased by 24.94% to $292.4 million in 2024, then surged by 140.97% to $704.7 million in 2025, then gained by 6.0% to $746.9 million in 2026.
• Per Business Quant, the three latest RVMD Total Non-Current Liabilities figures stand at $746.9 million (Q1 2026), $704.7 million (Q4 2025), and $652.5 million (Q3 2025).